Announcement PDF Market Announcement 14 December 2023 Neuren Pharmaceuticals Limited (ASX: NEU) – Trading Halt Description The securities of Neuren Pharmaceuticals Limited (‘NEU’) will be placed in trading halt at the request of NEU, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 18 December 2023 or when the announcement is released to the market. Issued by ASX Compliance 14 December 2023 ASX Limited Market Announcement 1/1 ASX Customer Service Centre 131 279 | asx.com.au 14 December 2023 Lisa Banh Senior Adviser, Listings Compliance By Email Dear Lisa, TRADING HALT REQUEST The Directors of Neuren Pharmaceuticals Limited (ASX Code: NEU) hereby request an immediate halt in trading of the Company’s securities. In accordance with Listing Rule 17.1, the Company: • advises that the reason for the request is to facilitate an orderly market in the Company’s securities pending an announcement in relation to the top line results of its Phase 2 clinical trial in Phelan-McDermid syndrome; • requests that the trading halt remain in place until the Company releases an announcement in relation the Phase 2 clinical trial in Phelan-McDermid syndrome or until the commencement of trading on Monday 18 December 2023, whichever is earlier; • confirms that it is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market regarding the trading halt. Yours sincerely Lauren Frazer CFO and Company Secretary Neuren Pharmaceuticals Limited ABN 72 111 496 130 Suite 201, 697 Burke Road, Camberwell, VIC 3124